Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma

Status Recruiting

Clinical Trial Summary

Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. There is no standard second-line treatment plan for patients who have failed first-line treatment. NY-ESO-1, a cancer testis antigen, is highly expressed in soft tissue tumors and is an ideal therapeutic target. Investigators aim to testify the safety and efficacy of NY-ESO-1 TCR-T cell in advanced soft tissue sarcoma.

Clinical Trial Description

Soft tissue sarcoma (STS) is a kind of solid tumor with high heterogeneity. The treatment of STS is complex and challenging, and surgery is still the main treatment method at present. For patients who are inoperable or advanced, medical treatment should be considered, mainly including chemotherapy and targeted treatment. At present, there is no standard second-line treatment plan for patients who failed first-line treatment. NY-ESO-1, a cancer testis antigen, is highly expressed in soft tissue tumors and is an ideal therapeutic target. Investigators aim to testify the safety and efficacy of NY-ESO-1 TCR-T cell in advanced soft tissue sarcoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05620693
Study type	Interventional
Source	Shenzhen University General Hospital
Contact	Li Yu, Dr
Phone	+8675521839178
Email	liyu@vip.163.com
Status	Recruiting
Phase	N/A
Start date	November 11, 2022
Completion date	December 1, 2028

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT05043649` - Camsirubicin + Pegfilgrastim to Determine MTD in ASTS	Phase 1
Recruiting	`NCT05146440` - Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination With Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor	Phase 1/Phase 2
Recruiting	`NCT05809830` - Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas	Phase 1/Phase 2
Not yet recruiting	`NCT06367075` - A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma	Phase 2
Recruiting	`NCT04874311` - Bintrafusp Alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma	Phase 2
Recruiting	`NCT05876715` - LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma	Phase 1/Phase 2
Recruiting	`NCT04757337` - Comparison of Oral Cyclophosphamide vs Doxorubicin in ≥65 Years Old Advanced or Metastatic Soft Tissue Sarcoma Patients	Phase 3
Recruiting	`NCT04705818` - Combining Epigenetic And Immune Therapy to Beat Cancer.	Phase 2
Terminated	`NCT05154630` - Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors	Phase 1/Phase 2
Recruiting	`NCT05099666` - Lurbinectedin + Doxorubicin In Leiomyosarcoma	Phase 1/Phase 2
Completed	`NCT03022448` - Geriatric Assessmen of Elderly "Unsuited" Patients Receiving Trabectedin in First Line Treatment For Advanced Soft Tissue Sarcomas (STS)
Recruiting	`NCT04204941` - Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma	Phase 3
Recruiting	`NCT05182164` - Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas	Phase 2
Recruiting	`NCT05180695` - HDM201 and Pazopanib in Patients With P53 Wild-type Advanced/Metastatic Soft Tissue Sarcomas	Phase 1/Phase 2
Terminated	`NCT04780464` - A 3 Arm Randomized Study on Health-related QoL of Elderly Patients With Advanced Soft Tissue Sarcoma	Phase 3